Geron Gets Green Light To Test Embryonic Stem Cell Therapy On Humans
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA lifted its clinical hold on Geron’s human embryonic stem cell therapy for spinal-cord injury, granting the company’s IND application and creating a hallelujah moment for frustrated believers in embryonic stem cell medicine.